Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Roche agrees $7.1bn deal for Telavant to boost drug pipeline
Ist Teil von
FT.com, 2023-10-23
Ort / Verlag
London: The Financial Times Limited
Erscheinungsjahr
2023
Link zum Volltext
Beschreibungen/Notizen
Roche plans to buy immunology company Telavant from Roivant Sciences and Pfizer for more than $7bn, as the drugmaker’s new chief executive seeks to replenish its drug pipeline. The Swiss company will acquire the rights to develop and manufacture Telavant’s potential drug for inflammatory bowel disease, which affects almost 8mn people worldwide. Thomas Schinecker, who took over as Roche chief executive in March, said the drug, which is ready to start a late-stage trial, had “transformational potential”.